Pibrentasvir

Pibrentasvir is an NS5A inhibitor antiviral agent. In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name "Mavyret" in the US and "Maviret" in the EU) for the treatment of hepatitis C. It is sold by Abbvie.